[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA32211B1 - Treatment of eye disorders - Google Patents

Treatment of eye disorders

Info

Publication number
MA32211B1
MA32211B1 MA33226A MA33226A MA32211B1 MA 32211 B1 MA32211 B1 MA 32211B1 MA 33226 A MA33226 A MA 33226A MA 33226 A MA33226 A MA 33226A MA 32211 B1 MA32211 B1 MA 32211B1
Authority
MA
Morocco
Prior art keywords
treatment
eye disorders
diabetic
emphysema
thanks
Prior art date
Application number
MA33226A
Other languages
Arabic (ar)
French (fr)
Inventor
Thomas Oligino
Chang Hahn
Timothy A Gillespy
Ramalinga Dharanipragada
Ellen Matzkin
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MA32211B1 publication Critical patent/MA32211B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

يتعلق الاختراع بعلاج لاضطرابات العين، مثل الانحطاط البقعي المرتبط بالعمر ، وتفضيلا ، اعتلال الشبكية السكري و الانتفاخ البقعي السكري، وذلك بفضل مركب من الصيغة i.The invention relates to the treatment of eye disorders, such as age-related macular degeneration, preferably, diabetic retinopathy and diabetic macular emphysema, thanks to a compound of formula i.

MA33226A 2008-03-10 2010-10-06 Treatment of eye disorders MA32211B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3507308P 2008-03-10 2008-03-10
PCT/US2009/036119 WO2009114373A1 (en) 2008-03-10 2009-03-05 Treatment for ocular-related disorders

Publications (1)

Publication Number Publication Date
MA32211B1 true MA32211B1 (en) 2011-04-01

Family

ID=40583469

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33226A MA32211B1 (en) 2008-03-10 2010-10-06 Treatment of eye disorders

Country Status (22)

Country Link
EP (1) EP2285378A1 (en)
JP (1) JP2011513488A (en)
KR (1) KR20110009084A (en)
CN (1) CN101965188A (en)
AR (1) AR070975A1 (en)
AU (1) AU2009223501A1 (en)
BR (1) BRPI0909659A2 (en)
CA (1) CA2717991A1 (en)
CL (1) CL2009000551A1 (en)
CO (1) CO6290691A2 (en)
CR (1) CR11644A (en)
DO (1) DOP2010000266A (en)
IL (1) IL207906A0 (en)
MA (1) MA32211B1 (en)
MX (1) MX2010008308A (en)
NI (1) NI201000131A (en)
NZ (1) NZ587906A (en)
RU (1) RU2010141560A (en)
SV (1) SV2010003658A (en)
TW (1) TW200950784A (en)
WO (1) WO2009114373A1 (en)
ZA (1) ZA201005337B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201034675A (en) 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100910488B1 (en) * 1999-12-24 2009-08-04 아벤티스 파마 리미티드 Azaindoles
JP2003523390A (en) * 2000-02-25 2003-08-05 メルク エンド カムパニー インコーポレーテッド Tyrosine kinase inhibitor
ES2535854T3 (en) * 2005-09-30 2015-05-18 Miikana Therapeutics, Inc. Substituted Pyrazole Compounds
CL2007002617A1 (en) * 2006-09-11 2008-05-16 Sanofi Aventis COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRAZIN-6-ILO; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT INFLAMMATION OF THE ARTICULATIONS, Rheumatoid Arthritis, TUMORS, LYMPHOMA OF THE CELLS OF THE MANTO.

Also Published As

Publication number Publication date
AU2009223501A1 (en) 2009-09-17
MX2010008308A (en) 2010-08-11
RU2010141560A (en) 2012-04-20
ZA201005337B (en) 2011-04-28
EP2285378A1 (en) 2011-02-23
AR070975A1 (en) 2010-05-19
JP2011513488A (en) 2011-04-28
BRPI0909659A2 (en) 2015-09-22
CL2009000551A1 (en) 2009-08-21
WO2009114373A1 (en) 2009-09-17
TW200950784A (en) 2009-12-16
DOP2010000266A (en) 2010-09-30
CN101965188A (en) 2011-02-02
CA2717991A1 (en) 2009-09-17
SV2010003658A (en) 2011-01-31
CO6290691A2 (en) 2011-06-20
CR11644A (en) 2010-11-22
NI201000131A (en) 2011-09-29
NZ587906A (en) 2011-12-22
KR20110009084A (en) 2011-01-27
IL207906A0 (en) 2010-12-30

Similar Documents

Publication Publication Date Title
GEP20146072B (en) New compounds
MA37571A1 (en) Pesticide compositions and processes
MY170713A (en) Treatment protocol of diabetes type 2
MX2015007916A (en) Peri-carbinols.
UA113051C2 (en) HETEROCYCLIC DERIVATIVES AND THEIR APPLICATIONS IN THE TREATMENT OF NEUROLOGICAL DISORDERS
MA35920B1 (en) Compounds for the treatment of spinal muscular atrophy
EA201001639A1 (en) COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND APPLICATION
TR201902788T4 (en) 1-arylcarbonyl-4-oxy-piperidine compounds useful in the treatment of neurodegenerative diseases.
EA201190217A1 (en) SUBSTITUTED 2-ACETAMIDO-5-ARIL-1,2,4-TRIAZOLONES AND THEIR APPLICATION
CU24083B1 (en) USEFUL OXAZINE DERIVATIVES AS BACE INHIBITORS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
ECSP066373A (en) IVABRADINE CHLORIDE HYDROCHLET BETA FORM, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
EA201200176A1 (en) OXAZIN DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
EA201100138A1 (en) 4-PHENOXYMETHYL-PIPERIDINES AS MODEL ACTIVITY GPR119
MY160468A (en) Novel amino azaheterocyclic carboxamides
SG178963A1 (en) Compounds as tyrosine kinase modulators
PH12014502624B1 (en) Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
BR112014008759A8 (en) TREATMENT OF EYE DISEASE
MA32505B1 (en) 5-alkynyl-PYRIMIDINE
CR20130264A (en) PIRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2
EA201500182A1 (en) 4-METHYL-2,3,5,9,9b-PENTAASACYCLOPENT [a] NAFTAIL
EA201200570A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
DK2257275T3 (en) Ketorolacrometamine compositions for the treatment or prevention of eye pain
ATE554076T1 (en) SULFOXIMINE SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNE MODULATORS, THEIR PRODUCTION AND THEIR USE AS MEDICATIONS
BRPI0720050A2 (en) 6-OXO-1,6-DIIDROPYRIMIDIN-2-ILAS IN THE TREATMENT OF PROLIFERATIVE DISEASES
GEP20156315B (en) Oxazoline and isoxazoline derivatives as crac modulators